Semaglutide vs Tirzepatide: 2026 Weight Loss Comparison

Semaglutide vs tirzepatide: the short answer

Semaglutide and tirzepatide are the two most effective GLP-1 medications for weight loss available in 2026, and the practical difference comes down to mechanism and magnitude. Semaglutide — the molecule in Ozempic® and Wegovy® — activates a single gut-hormone receptor (GLP-1). Tirzepatide — the molecule in Mounjaro® and Zepbound® — activates two receptors (GIP and GLP-1), and in head-to-head data produces greater average weight loss. The pivotal direct comparison, SURMOUNT-5 (New England Journal of Medicine, 2025), reported approximately 20.2% mean weight loss with tirzepatide versus approximately 13.7% with semaglutide over 72 weeks.

That said, semaglutide has a longer real-world track record, is well tolerated by many patients, and is frequently the lower-cost option. Neither is universally "better" — the right choice depends on weight-loss goals, tolerability, cost, and provider judgment. Both are available as compounded medications through licensed providers at Cora Health. Compounded medications are not FDA-approved and are not therapeutically equivalent to the branded products. Individual results vary.

How they differ: single vs dual receptor agonist

The core difference is the number of gut-hormone receptors each medication activates. Semaglutide is a single GLP-1 (glucagon-like peptide-1) receptor agonist: it mimics the GLP-1 hormone the gut releases after eating, which reduces appetite, slows gastric emptying, and improves the insulin response to food. Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. The added GIP activity is widely credited for tirzepatide's stronger weight-loss and glycemic effects, though the precise mechanism is still being characterized in the published literature.

In practical terms, both medications make a sustainable caloric deficit easier by reducing hunger and food preoccupation. Tirzepatide's second pathway appears to add an extra layer of appetite and metabolic effect on top of what GLP-1 alone delivers. Neither medication "burns fat" directly — both reshape appetite and metabolism so the body more readily draws on stored energy.

Weight loss head-to-head: what the trials show

All trial data below comes from studies of FDA-approved semaglutide and tirzepatide, not compounded versions. Compounded medications have not been independently evaluated in clinical trials.

For semaglutide, the pivotal weight-management trial is STEP 1 (Wilding et al., New England Journal of Medicine, 2021), which reported 14.9% mean weight loss over 68 weeks at the 2.4mg weekly dose. For tirzepatide, the pivotal trial is SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), which reported 22.5% mean weight loss over 72 weeks at the 15mg weekly dose.

The most direct evidence is SURMOUNT-5 (New England Journal of Medicine, 2025), the first head-to-head trial of the two molecules: over 72 weeks, FDA-approved tirzepatide produced approximately 20.2% mean weight loss versus approximately 13.7% for FDA-approved semaglutide 2.4mg — a clinically meaningful gap favoring tirzepatide. These figures reflect branded products combined with lifestyle intervention. Individual results vary substantially based on starting weight, adherence, diet, exercise, and other factors.

Side effects: how the two compare

Both medications share the same primary side-effect profile because both act on the gut. The most common side effects are gastrointestinal — nausea, diarrhea, constipation, and vomiting — and are most pronounced during dose escalation, easing for most patients as the body adapts. In the STEP 1 trial, nausea affected roughly 44% of semaglutide patients; in SURMOUNT-1, nausea affected roughly 29% of tirzepatide patients at the 15mg dose. Direct comparisons suggest broadly similar tolerability, with some evidence that tirzepatide's gastrointestinal effects are comparable to or slightly lower than semaglutide's at equivalent stages of titration despite greater weight loss.

Both carry the same boxed warning regarding thyroid C-cell tumors observed in rodent studies and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Both can increase the risk of pancreatitis and gallbladder problems. Side effects are managed the same way for either molecule: gradual titration, smaller meals, hydration, adequate protein, and close provider contact during dose changes. Any new or severe symptom should be discussed with your provider.

Dosing and titration

Both medications are once-weekly subcutaneous injections that start low and titrate up over months to balance tolerability against effect. The dose numbers differ because the molecules differ.

Semaglutide for weight management titrates from 0.25mg weekly up to a 2.4mg maintenance dose, typically over 16 to 20 weeks. Tirzepatide titrates from 2.5mg weekly up to a 15mg maximum dose over a similar period. In both cases the starter dose is not therapeutic for weight loss — it exists to let the body adapt. Many patients reach an effective maintenance dose below the maximum and sustain weight loss there. The titration schedule is set by the prescribing provider based on individual response and tolerability, not a fixed calendar.

Cost: compounded vs brand-name

Brand-name semaglutide and tirzepatide carry similar retail list prices — generally $1,000 or more per month without insurance — though manufacturer self-pay programs (NovoCare for semaglutide, LillyDirect for tirzepatide) lower that for some patients. Compounded versions, prepared by US-licensed 503A pharmacies under a patient-specific prescription, are substantially less expensive. At Cora Health, standard-plan pricing is flat across all doses and all-inclusive of provider consultation, medication, and shipping.

Compounded medications are not FDA-approved and are not therapeutically equivalent to the branded products. The FDA does not review compounded drugs for safety, effectiveness, or manufacturing quality before they reach patients, so the single most useful signal a patient can check is whether a provider publicly names its compounding pharmacy. Cora Health names VialsRx (US-licensed 503A) and Hallandale Pharmacy (PCAB-accredited, operating since 2003) so credentials can be independently verified.

Which one is right for you?

There is no universally correct answer — the choice is clinical and individual. Tirzepatide tends to be the stronger option for patients prioritizing maximum average weight loss, supported by the SURMOUNT-5 head-to-head data. Semaglutide may suit patients who want the molecule with the longest real-world track record, who tolerate it well, or for whom cost is the deciding factor.

Other factors a licensed provider weighs include medical history, prior GLP-1 experience, other medications, contraindications, and how a patient responds during titration. Some patients begin on one molecule and switch to the other based on tolerability or a weight-loss plateau. This is a decision to make with a licensed provider, not a self-diagnosis — Cora Health connects patients with providers at Wasef Health, PC who evaluate each case and prescribe only when clinically appropriate.

How to access either medication through Cora Health

Cora Health offers both compounded semaglutide (Essential Plan) and compounded tirzepatide (Premium Plan) through licensed providers. Cora Health does not prescribe medication; the providers at Wasef Health, PC evaluate each patient through an online health assessment and write a patient-specific prescription only when clinically appropriate. Prescriptions are fulfilled by US-licensed 503A compounding pharmacies, including VialsRx and Hallandale Pharmacy, and shipped to all 50 US states. The process from intake to first dose typically takes 3 to 7 business days, with ongoing provider support for dose adjustments and side-effect management. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products. Individual results vary.